Heart Disease Does Not Care About Your Deadlift.
Heart disease kills more men than every cancer combined. One in four men will die from cardiovascular disease. The average age of first heart attack in men is 65, but atherosclerosis begins decades earlier—plaque buildup is detectable in some men by their 30s.
The fitness community has a blind spot here. Men who train hard assume cardiovascular health comes with the territory. It does not. Anabolic compounds, chronic inflammation, poor sleep, high stress, and family history all contribute to cardiac risk independent of how much you squat.
Peptide research in cardiac applications is among the most exciting and least discussed areas in the biohacking space. TB-500 has dedicated cardiac repair research. BPC-157 modulates nitric oxide and blood pressure. MOTS-C addresses the metabolic underpinning of cardiometabolic disease.
TB-500: Cardiac Tissue Repair.
TB-500 (Thymosin Beta-4 fragment) has the most cardiac-specific research of any peptide in common use. Thymosin Beta-4 is naturally present in cardiac tissue, and research demonstrates its role in cardiac development, repair after injury, and protection against ischemic damage.
Published studies show TB-500 promotes cardiomyocyte survival after ischemic injury, stimulates new blood vessel formation in cardiac tissue, reduces cardiac fibrosis (scar tissue from heart damage), and activates cardiac progenitor cells.
The clinical relevance: After a cardiac event (heart attack, myocarditis, ischemic injury), the heart forms scar tissue just like any other organ. That scar tissue does not contract like healthy heart muscle, reducing cardiac output. TB-500 research demonstrates reduction in cardiac scar formation and promotion of functional tissue preservation.
Dosing: 2-2.5 mg subcutaneous twice weekly. TB-500 distributes systemically, reaching cardiac tissue through normal circulation. No cardiac-specific injection route is needed or appropriate for self-administration.
BPC-157: Blood Pressure and Vascular Health.
BPC-157 modulates nitric oxide (NO) signaling—the primary mechanism by which blood vessels dilate and blood pressure is regulated. Research demonstrates BPC-157's ability to normalize blood pressure in both hypertensive and hypotensive models, suggesting a regulatory (not just lowering) effect on vascular tone.
Additional cardiovascular research shows BPC-157 protects against thrombosis (blood clot formation), reduces vascular inflammation, and promotes endothelial function—the health of the cells lining your blood vessels.
Endothelial dysfunction is the earliest detectable stage of atherosclerosis, often present 10-20 years before a clinical event. BPC-157's endothelial protective effects place it in the prevention category, not just the treatment category.
Dosing: 250-500 mcg subcutaneous daily. The cardiovascular effects are systemic—injection site does not matter for cardiac benefit.
MOTS-C: The Metabolic Shield.
Most heart disease is metabolic heart disease. Insulin resistance, visceral fat, chronic inflammation, and dyslipidemia create the environment where atherosclerosis thrives. Fixing the metabolic foundation is cardiac prevention at its most fundamental.
MOTS-C activates AMPK, improving insulin sensitivity, glucose homeostasis, and mitochondrial function. These are the same metabolic pathways that drugs like metformin target—and metformin has been studied extensively for cardioprotection.
For men with metabolic syndrome (elevated fasting glucose, high triglycerides, low HDL, central obesity, elevated blood pressure—3 of 5 criteria qualifies), MOTS-C addresses multiple cardiovascular risk factors simultaneously through a single metabolic pathway.
Dosing: 5-10 mg weekly, split into daily subcutaneous injections. Metabolic improvements measurable in bloodwork within 4-6 weeks.
The Cardiac Protection Stack.
Prevention (no known cardiac disease): BPC-157 250 mcg daily for endothelial protection + MOTS-C 5 mg weekly for metabolic optimization. Add annual cardiac screening (lipid panel, hsCRP, coronary calcium score after age 40).
Risk reduction (metabolic syndrome, family history, or elevated inflammatory markers): BPC-157 250-500 mcg daily + MOTS-C 5-10 mg weekly + TB-500 2 mg weekly for anti-inflammatory support. Aggressive lifestyle modification (diet, exercise, stress management, sleep) alongside peptide support.
Post-event support (after cardiac event, with physician oversight): TB-500 2.5 mg twice weekly for cardiac tissue support. BPC-157 500 mcg daily for vascular recovery. Continue through the cardiac rehabilitation period. All post-event peptide use should be disclosed to your cardiologist.
Monitoring: Lipid panel, fasting insulin, hsCRP, and blood pressure quarterly. Coronary calcium score at baseline and every 3-5 years after age 40. Echocardiogram if any structural concerns exist.
The Conversation with Your Cardiologist.
Cardiologists are not going to prescribe peptides. But they need to know if you are using them. BPC-157's effects on nitric oxide and blood pressure could interact with antihypertensive medications. TB-500's effects on cardiac tissue are relevant to post-event monitoring. MOTS-C's metabolic effects could alter diabetes medication requirements.
Frame it clearly: "I am using research peptides that may affect cardiovascular signaling. I want to ensure my monitoring is appropriate." Your cardiologist may not endorse the approach, but they will adjust monitoring accordingly.
Never hide peptide use from a physician managing your cardiac health. The interaction potential is real, and your cardiologist cannot protect you from what they do not know about.
◆ Key Takeaway
TB-500 has dedicated cardiac tissue repair research (cardiomyocyte survival, angiogenesis, fibrosis reduction). BPC-157 protects endothelial function and modulates blood pressure through nitric oxide pathways. MOTS-C addresses the metabolic syndrome that drives most cardiac disease. Stack based on risk level: prevention, risk reduction, or post-event support. Always disclose peptide use to your cardiologist.